FDA is launching a pilot project to integrate Risk Evaluation and Mitigation Strategies (REMS) into Structured Product Label (SPL) format. This will facilitate the sharing of documents and ease the integration of critical information into pharmacy and hospital IT systems.
As with most pilot programs, participation is on a voluntary basis, and open to application holders of drugs with REMS. With the program, FDA intends to “evaluate a potential approach to converting REMS into SPL format and evaluate the usefulness of the REMS information to be provided in SPL format.”
FDA is accepting requests from candidates that meet the qualifications and are interested in participating until December 7, 2015. The program will last for four months, and will take place from October 6, 2015 to February 3, 2016. For more details on the program or how to register, see the announcement in the Federal Register, here.
This pilot program is one of FDA’s four “priority projects,” which were introduced in a July 2013 meeting in an attempt to improve the REMS program.
October 8, 2015
Guidance Document Guidance for Industry and Food and Drug Administration Staff JUNE 2022 This guidance document provides FDA's recommendations on the information, technical performance assessment,...
October 8, 2015
FDA wants to know how much of the information presented in television advertisements consumers understandGem, and how much more information they could handle. In an effort to answer these questions,...
October 8, 2015
Each EU Health Authority has published a wide range of information regarding coronavirus, COVID-19, on their websites. In this blog we will try to guide you through all these recommendations and...